N- (phenyl-oxazol-4-ylmethoxymethyl)-cycl ohexyl-succinic acid amide derivatives and related compounds which are used as PPAR-ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes

Details for Australian Patent Application No. 2005274493 (hide)

Owner Sanofi-Aventis Deutschland GmbH

Inventors Glombik, Heiner; Knieps, Stephanie; Schaefer, Hans-Ludwig; Falk, Eugen; Stapper, Christian; Keil, Stefanie; Wendler, Wolfgang

Agent Watermark

Pub. Number AU-A-2005274493

PCT Pub. Number WO2006/018116

Priority 10 2004 039 509.8 14.08.04 DE

Filing date 30 July 2005

Wipo publication date 23 February 2006

International Classifications

C07D 263/32 (2006.01) Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings

A61K 31/421 (2006.01) - 1,3-Oxazoles, e.g. pemoline, trimethadione

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

8 March 2007 PCT application entered the National Phase

  PCT publication WO2006/018116 Priority application(s): WO2006/018116

23 February 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005274494-Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments

2005274492-2 - { - 3 2 - (phenyl)-oxazol-4-ylmethoxyl-cyclohexy lmethoxy}-propionic acid derivatives used as PPAR ligands (peroxisome proliferator-activated receptors) for the treatment of hyperlipidaemie and diabetes